Genetic Technologies Announces U.S. Patent Office Allows First Patent for ImmunAid

Genetic Technologies Announces U.S. Patent Office Allows First Patent for 
ImmunAid 
MELBOURNE, AUSTRALIA -- (Marketwired) -- 07/10/13 --  Genetic
Technologies Limited (ASX: GTG) (NASDAQ: GENE) is pleased to announce
that ImmunAid Limited, in which GTG holds a 45% direct equity
interest and is currently the largest shareholder, has just been
advised that its first U.S. patent has now been formally allowed by
the relevant U.S. Government authority, the United States Patent and
Trademark Office. 
As previously reported to the Market, ImmunAid has been working since
2001 to research, develop and refine an entirely new -- and
potentially revolutionary -- treatment strategy for patients with
life-threatening diseases such as cancer and auto-immune disease,
whereby the unique immune cycle of each individual patient is
monitored on an individual basis, in order to determine the precise
optimal time to deliver treatment to that individual patient. Such
treatment might still include chemotherapy, or radiotherapy or
immunotherapy, etc. -- but in every case, the treatment is carefully
administered within a unique "window of opportunity" which ImmunAid
can now identify for each individual patient. 
This new treatment strategy has since been tested on cancer patients
in Australia and USA with extremely encouraging results and is now
steadily building a momentum of supporting articles and commentaries
in relevant medical journals, medical conferences and the general
media.  
In late 2011, the granting of a first European patent to ImmunAid
justified a first round of funding for ImmunAid, and it may now be
assumed that this latest achievement -- of a first patent being
allowed in USA -- will likewise justify a second round of funding and
investor support for ImmunAid to enable it to further expand the
application of its breakthrough in human disease and even in animal
disease, thereby supporting ImmunAid's further progress towards the
commercialization of this exciting new technology. 
About Genetic Technologies Limited
 Genetic Technologies was an early
pioneer in recognizing important new applications for "non-coding"
DNA (Deoxyribonucleic Acid). The Company has since been granted
patents in 24 countries around the world, securing intellectual
property rights for
 particular uses of non-coding DNA in genetic
analysis and gene mapping across all genes in all species. Its
business strategy is the global commercialization of its patents
through an active out-licensing program and the global expansion of
its oncology and cancer management diagnostics portfolio. Genetic
Technologies is a company listed on both the ASX and NASDAQ with
operations in the USA and Australia. For more information, please
visit www.gtglabs.com. 
Safe Harbor Statement
 Any statements in this press release that
relate to the Company's expectations are forward-looking statements,
within the meaning of the Private Securities Litigation Reform Act.
The Private Securities Litigation Reform Act of 1995 (PSLRA)
implemented several significant substantive changes affecting certain
cases brought under the federal securities laws, including changes
related to pleading, discovery, liability, class representation and
awards fees and of 1995. Since this information may involve risks and
uncertainties and are subject to change at any time, the Company's
actual results may differ materially from expected results.
Additional risks associated with Genetic Technologies' business can
be found in its periodic filings with the SEC. 
FOR FURTHER INFORMATION PLEASE CONTACT
Dr. Mervyn Jacobson
VP Global Licensing and IP
Genetic Technologies Limited
Phone: +61 419 657 915 
Ms. Laura Forman (USA)
Blueprint Life Science Group
+1 (415) 375 3340, Ext. 103 
 
 
Press spacebar to pause and continue. Press esc to stop.